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The fibroblast growth factors (FGF) FGF-1 and FGF-2 are
often deregulated in hepatocellular carcinoma (HCC).
Information is missing on the role of other FGF-family
members for hepatocarcinogenesis. We therefore deter-
mined the function of FGF-8, FGF-17 and FGF-18 in the
development and progression of liver cancer. Half of the
rat liver tumors studied showed enhanced expression of
FGF-18. In about 50% of human HCC, FGF-8, FGF-17
and FGF-18 and the corresponding FGF-receptors 3 and 4
were found to be upregulated. For functional studies we
chose primary co-cultures of normal and premalignant
(GSTp+) rat hepatocytes. DNA synthesis was significantly
higher in GSTp+ than in normal hepatocytes indicating an
inherent growth advantage of the premalignant cell pop-
ulation. FGF-8 and FGF-18 stimulated DNA preferentially
in GSTp+ hepatocytes, while FGF-17 exhibited no effect.
In HCC-derived cell lines FGF-8, FGF-17 and FGF-18 stim-
ulated growth, which involved phosphorylation of ERK1/
2 and S6. Conclusions: FGF-8 and FGF-18 induced prefer-
ential growth of (pre)malignant hepatocytes and are
highly upregulated in liver tumors indicating auto- and/or
paracrine stimulation during formation and progression
of the tumors. The results also show considerable similar-
ities in the role of these FGFs in rat and human hepatocar-
cinogenesis implying that the molecular mechanisms
underlying chemically induced rat hepatocarcinogenesis
and human hepatocarcinogenesis are often identical.
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